6/11/2013 Piper Jaffray Reiterated Rating Arena Pharmaceuticals (ARNA) Overweight $9.00 $12.50
Since Piper upgraded Arena, Lonnol Coats head of Eisia U.S. said recently that they see $150M Sales by the end of this year, That would put Pipers valuation at $20plus
5/6/2013 Credit Suisse Lower Price Target Arena Pharmaceuticals (ARNA) $6.00 $5.00
But wait as minute, Credit Suisse said last week "Credit Suisse estimates Belviq could crack the "blockbuster" mark of $1 billion in U.S. sales by 2018. Arena is also targeting a launch in South Korea next year, and Belviq is awaiting approval in several other countries" the oldest game in the book, tell everyone else to sell while we up our stake 451%.
3/5/2013 JPMorgan Chase Lower Price Target Arena Pharmaceuticals (ARNA) $7.00
But wait a minute. Cory Kasimov, an analyst with J.P. Morgan, he rated Arena as neutral recently. Arena was sitting in the mid $8's when this was quoted.
2/6/2013 Leerink Swann Initiated Coverage Arena Pharmaceuticals (ARNA) Outperform $11.00 $12.00
1/28/2013 TheStreet Reiterated Rating Arena Pharmaceuticals (ARNA) Sell
Who cares what Jimbo thinks. I don't. (Youtube deep capture, Jimbo will tell you how they do it)
11/7/2012 Jefferies Group Set Price Target Arena Pharmaceuticals (ARNA) Buy $14.00
6/28/2012 Needham & Company Reiterated Rating Arena Pharmaceuticals (ARNA) Hold
6/25/2012 BMO Capital Markets Arena Pharmaceuticals (ARNA) Market Perform $10.00
Sentiment: Strong Buy
Thank you - FYI - The most important factor of course is that the med sales are rising at a good rate, however another important factor related specificaly to the PPS is that the sub-sector of the revitalized weight-loss meds is recognized by the analysts as being here to stay.
Sentiment: Strong Buy
The fact is Eisia's estimates are probably low as they would not want to over shoot expectations.
$150M by the end of the year means $300M in one year. Arena will receive $134M in milestones before the 1yr mark. If their $300M a year is correct, that gives Arena roughly $105M a year plus milestones. add an additional $1B for getting belviq to market in.
In case you missed it, Oppenheimer & Co is also now saying Belviq, blockbuster $1B in sales
Thanks for providing this information. Although the analysts have set price targets higher than the current price, they are still way too conservative. ARNA should be over $20 a share NOW, based on its risk/reward profile. In my opinion, ARNA will be over $50 easily within a couple of years and even that price should be considered a very conservative estimate.